US strengthens registration requirements for institutional review boards
This article was originally published in SRA
The US Food and Drug Administration and the Office for Human Research Protections have strengthened the registration requirements for institutional review boards that oversee clinical investigations of FDA-regulated products and federally supported research, respectively1,2. The new measures, which come into effect on 14 July, aim to create a first-ever comprehensive database of IRBs that will make it easier for the FDA and the OHRP to inspect IRBs and to convey information to them.
You may also be interested in...
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.